Content about Sjögren's syndrome

May 13, 2013
N.J. law designed to address prescription eye drop adherence

New Jersey Gov. Chris Christie signed legislation into law that will allow patients using prescription eye drops to get early refills in order to prevent interruptions in therapy.

TRENTON, N.J. — New Jersey Gov. Chris Christie signed legislation into law Monday that will allow patients using prescription eye drops to get early refills in order to prevent interruptions in therapy.

April 2, 2013
Patients undergoing chemotherapy can find relief with the Natural Dentist

The Natural Dentist has launched “Rinse for Relief,” an online resource for proper oral care aimed at cancer patients suffering from mouth sores and other oral ailments, the fourth most common side effect of chemotherapy treatments.

MADISON, N.J. — The Natural Dentist has launched “Rinse for Relief,” an online resource for proper oral care aimed at cancer patients suffering from mouth sores and other oral ailments, the fourth most common side effect of chemotherapy treatments. The initiative included the unveiling of RinseForRelief.com and a giveaway of one free sample of Healthy Gums Mouth Rinse, an all-natural product that works as an effective daily cleanser and helps prevent and reduce gum bleeding and inflammation.

October 9, 2012
Ranbaxy launches authorized generic autoimmune drug

Ranbaxy Labs has launched an authorized generic drug for treating dry mouth associated with an autoimmune disorder, the company said Tuesday.

PRINCETON, N.J. — Ranbaxy Labs has launched an authorized generic drug for treating dry mouth associated with an autoimmune disorder, the company said Tuesday.

The India-based generic drug maker announced the launch of cevimeline hydrochloride in the 30-mg strength under an agreement with parent company Daiichi Sankyo. The drug is used in patients with Sjogren's syndrome, which affects the moisture-producing glands.

March 8, 2012
Portable oral care expected to grow

Portable oral care continues to be on the upswing, and it is likely that the segment will continue to experience growth as Americans age and take more medications and oral health conditions also rise.

Portable oral care continues to be on the upswing, and it is likely that the segment will continue to experience growth as Americans age and take more medications and oral health conditions also rise.

December 23, 2011
Baxter, Momenta partner on biosimilar development

Baxter and Momenta have agreed to partner to develop and market biosimilar drugs to treat cancer, autoimmune disorders and other chronic conditions.

NEW YORK — Baxter and Momenta have agreed to partner to develop and market biosimilar  drugs to treat cancer, autoimmune disorders and other chronic conditions.

September 12, 2011
Taking it to-go

Portable oral care continues to experience strong growth and, if prior sales periods are any indication of what’s ahead, the segment will likely continue to flourish.

Portable oral care continues to experience strong growth and, if prior sales periods are any indication of what’s ahead, the segment will likely continue to flourish.

Sales of portable oral care for the 52 weeks ended Aug. 7 at food, drug and mass (excluding Walmart) experienced double-digit growth, climbing 43% to $13.2 million, according to SymphonyIRI Group.

January 24, 2011
Study: TheraTears Nutrition improves eye health

Advanced Vision Research on Monday announced results from a pilot trial published in the journal Cornea that demonstrated a reduction in dry-eye symptoms and an increase in tear volume and tear flow for those patients taking TheraTears Nutrition, an optimized blend of omega-3 oils.

WOBURN, Mass. — Advanced Vision Research on Monday announced results from a pilot trial published in the journal Cornea that demonstrated a reduction in dry-eye symptoms and an increase in tear volume and tear flow for those patients taking TheraTears Nutrition, an optimized blend of omega-3 oils.

Almost 3-in-4 symptomatic dry-eye patients who received the omega-3 supplement reported having no symptoms of dry eye after 90 days. In the placebo group, only 7% had a complete reduction of symptoms.

December 13, 2010
OCuSOFT relaunches Tears Again advanced Liposome Spray

OCuSOFT, Inc., a leading maker of remedies for the treatment of ocular surface disease, has relaunched Tears Again advanced Liposome Spray, a unique eyelid spray for Meibomian Gland Dysfunction sufferers. Used in conjunction with OCuSOFT Lid Scrub Eyelid Cleanser, the new eyelid spray is ideal to promote good eyelid hygiene and healthy eyes and to help provide relief from eyelid irritation throughout the day, according to the company.

RICHMOND, Texas — OCuSOFT, Inc., a leading maker of remedies for the treatment of ocular surface disease, has relaunched Tears Again advanced Liposome Spray, a unique eyelid spray for Meibomian Gland Dysfunction sufferers. Used in conjunction with OCuSOFT Lid Scrub Eyelid Cleanser, the new eyelid spray is ideal to promote good eyelid hygiene and healthy eyes and to help provide relief from eyelid irritation throughout the day, according to the company.

October 11, 2010
Alcon introduces new lubricant eye drops

Alcon on Monday announced the launch of Systane Balance lubricant eye drops, formulated with HP...

HUENENBERG, Switzerland Alcon on Monday announced the launch of Systane Balance lubricant eye drops, formulated with HP Guar, borate, sorbitol, propylene glycol and Alcon’s exclusive LipiTech System -- an emulsion technology of mineral oil and an anionic phospholipid. The new eye drop is designed to restore the lipid layer and the natural tear film to allow for relief of dry-eye symptoms.

 

September 22, 2010
Alcon's TobraDex ST treats inflammatory eye conditions

Eyecare company Alcon has launched a new drug for inflammatory eye conditions....

HUENENBERG, Switzerland Eyecare company Alcon has launched a new drug for inflammatory eye conditions.

 

Alcon announced the launch of TobraDex ST (tobramycin, dexamethasone ophthalmic suspension) in the 0.3%/0.5% strength. The drug is used to treat inflammatory eye conditions treatable with corticosteroids and where bacterial infection or risk of infection exists.

 

 

September 12, 2010
Q&A: Eyelid clean-up

At the ECRM Health Care EPPS conference, OcuSoft presented a pair of new offerings. Drug...

At the ECRM Health Care EPPS conference, OcuSoft presented a pair of new offerings. Drug Store News caught up with OcuSoft president and CEO Cynthia Barratt for a rundown on eye care today.

Drug Store News: What is the opportunity within eyelid cleansers?

August 23, 2010
Roche to acquire BioImagene

Swiss drug maker Roche will acquire a U.S. diagnostics company that develops technology used to...

BASEL, Switzerland Swiss drug maker Roche will acquire a U.S. diagnostics company that develops technology used to create images of patients’ tissue samples.

Roche announced that it would acquire all of Sunnyvale, Calif.-based BioImagene for $100 million. BioImagene works in the field of digital pathology, a technology that allows the capturing, management and analysis of images of patients’ tissue samples, creating high-resolution images from glass microscope slides.